- Home
- AKBA vs EFR Comparison
AKBA vs EFR Comparison
Compare AKBA & EFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- EFR
- Stock Information
- Founded
- AKBA 2007
- EFR 2003
- Country
- AKBA United States
- EFR United States
- Employees
- AKBA N/A
- EFR N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- EFR Trusts Except Educational Religious and Charitable
- Sector
- AKBA Health Care
- EFR Finance
- Exchange
- AKBA Nasdaq
- EFR Nasdaq
- Market Cap
- AKBA 336.2M
- EFR 382.5M
- IPO Year
- AKBA 2014
- EFR N/A
- Fundamental
- Price
- AKBA $1.91
- EFR $12.97
- Analyst Decision
- AKBA Strong Buy
- EFR
- Analyst Count
- AKBA 1
- EFR 0
- Target Price
- AKBA $7.50
- EFR N/A
- AVG Volume (30 Days)
- AKBA 2.2M
- EFR 88.6K
- Earning Date
- AKBA 11-07-2024
- EFR 01-01-0001
- Dividend Yield
- AKBA N/A
- EFR 9.43%
- EPS Growth
- AKBA N/A
- EFR N/A
- EPS
- AKBA N/A
- EFR 1.69
- Revenue
- AKBA $169,879,000.00
- EFR N/A
- Revenue This Year
- AKBA N/A
- EFR N/A
- Revenue Next Year
- AKBA $30.85
- EFR N/A
- P/E Ratio
- AKBA N/A
- EFR $7.74
- Revenue Growth
- AKBA N/A
- EFR N/A
- 52 Week Low
- AKBA $0.80
- EFR $10.95
- 52 Week High
- AKBA $2.48
- EFR $13.29
- Technical
- Relative Strength Index (RSI)
- AKBA 49.15
- EFR 50.47
- Support Level
- AKBA $1.74
- EFR $12.76
- Resistance Level
- AKBA $1.90
- EFR $12.96
- Average True Range (ATR)
- AKBA 0.08
- EFR 0.11
- MACD
- AKBA -0.02
- EFR -0.02
- Stochastic Oscillator
- AKBA 34.38
- EFR 51.35
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About EFR Eaton Vance Senior Floating-Rate Fund of Beneficial Interest
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of health care, industrial equipment, lodging and casinos, oil and gas, publishing, radio and television, telecommunications, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.